Glucagon Receptor Antagonist: Research Data on HFpEF Treatment
Abstract: Glucagon receptor antagonists (GRAs) show promise for HFpEF by reducing gluconeogenesis and improving cardiac energetics. Current research data indicates GRA peptides (e.g., LY2409021) exhibit high receptor specificity but face bioavailability challenges versus small molecules. Market trends favor injectable GLP-1/GRA hybrids for metabolic-cardiac synergy. Key product parameters include half-life (>24h), purity (>98%), and endotoxin levels (<0.5 EU/mg). Leading brands (Novo Nordisk, Eli Lilly) dominate Phase II trials, while generic peptide manufacturers lack HFpEF-specific certifications. Selection criteria prioritize GMP-certified facilities with stability data (>2 years at 2-8°C). Logistics require cold-chain compliance (2-8°C) and lyophilized formulations to mitigate degradation. Industry outlook projects 12.4% CAGR through 2030, driven by HFpEF’s unmet need.